Akèy › Kansè Poumon ki pa ti selil › Missouri › St. Louis
Etid klinik pou Kansè Poumon ki pa ti selil nan St. Louis, MO
73 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote St. Louis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Ap rekriteFaz 3
- Cancer Care Center of O'Fallon, O'Fallon · 16 mi lwen
- HSHS Saint Elizabeth's Hospital, O'Fallon · 16 mi lwen
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Washington University School of Medicine, St Louis
- Veteran's Affairs Medical Center - Saint Louis, St Louis
- Mercy Hospital South, St Louis
- ak 7 plis
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Washington University Medicine, St Louis
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Ap rekriteFaz 2
- Missouri Baptist Medical Center, St Louis
- Cancer Care Center of O'Fallon, O'Fallon · 16 mi lwen
- HSHS Saint Elizabeth's Hospital, O'Fallon · 16 mi lwen
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine in St. Louis, St Louis
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- Washington University School of Medicine ( Site 3279), St Louis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Washington University, School of Medicine, St Louis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Mercy Hospital South, St Louis
- Mercy Hospital Saint Louis, St Louis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- Washington University Center for Advanced Medicine, St Louis
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, St Louis
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Washington University School of Medicine - Siteman Cancer Center, St Louis
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Washington University School Of Medicine, St Louis
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- Mercy South - David M Sindelar Cancer Center ( Site 0098), St Louis
- Mercy Research - David C. Pratt Cancer Center ( Site 0006), St Louis
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Washington University, St Louis
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Bridgeton · 15 mi lwen
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Washington University in St Louis, St Louis
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Washington University School Of Medicine, St Louis
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, St Louis
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- ak 4 plis
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Missouri Baptist Medical Center, St Louis
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Cancer Care Specialists of Illinois (CCSI), O'Fallon · 16 mi lwen
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Local Institution - 0140, St Louis
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Ap rekriteFaz 3
- Local Institution - 0685, Fenton · 15 mi lwen
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- SSM Health Cancer Care - St. Clare, Fenton · 15 mi lwen
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- Washington University School of Medicine, St Louis
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Bridgeton · 15 mi lwen
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- Washington University, St Louis
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, St Louis
- Clinical Study Site, St Louis
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Washington University, St Louis
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2/3
- Washington University-School of Medicine /ID# 262759, St Louis
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Siteman Cancer Center - Washington University Medical Campus, St Louis
A Study of KK2269 in Adult Participants With Solid Tumors
Ap rekriteFaz 1
- Washington University, St Louis
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Missouri Baptist Medical Center, St Louis
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine - Siteman Cancer Center, St Louis
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Bridgeton · 15 mi lwen
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, St Louis
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University, Siteman Cancer Center, St Louis
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site, St Louis
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- ak 4 plis
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Ap rekriteFaz 2
- Washington University School of Medicine-Sitemen Cancer Center, St Louis
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Siteman Cancer Center - Washington University, St Louis
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Ap rekriteFaz 3
- Barnes-Jewish Hospital - Siteman Cancer Center (Washington University - St. Louis), St Louis
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 3
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- ak 4 plis
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Ap rekriteFaz 1/2
- Washington University School of Medicine, St Louis
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Ap rekriteEtid obsèvasyon
- Mercy Hospital - South, St Louis
- Mercy Hospital -STL, St Louis
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- University of Kansas Cancer Center - Overland Park, Overland · 10 mi lwen
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Washington University, St Louis
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- Siteman Cancer Center, St Louis
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, St Louis
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Washington University, St Louis
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, St Louis
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Mercy Hospital Saint Louis, St Louis
- ak 2 plis
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
- Washington University Infusion Center Pharmacy, St Louis
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Ap rekriteFaz 2
- Siteman Cancer Center, Washington University, St Louis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- BJC Outpatient Center at Sunset Hills, Sunset Hills · 13 mi lwen
- ak 1 plis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- ak 7 plis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- ak 4 plis
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Washington University School of Medicine, St Louis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Mercy Hospital Saint Louis, St Louis
- ak 4 plis
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Washington University, St Louis
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Mercy Clinic Oncology and Hematology - Sindelar Cancer Center, St Louis
- Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center, St Louis
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University Medical Campus, St Louis
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Ap rekrite
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO, St Louis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, St Louis
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Washington University, St Louis
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
- Seattle, WA53 etid
Lòt etid nan St. Louis
- Kansè nan tete64 etid
- Kansè Metastatik54 etid
- Kansè kolorektal50 etid
- Kansè (tout kalite)46 etid
- Kansè pwostat46 etid
- Kansè poumon39 etid
- Kansè ovè38 etid
- Kansè pankreyas33 etid
- Kansè Endomèt29 etid
- Karsinòm selil skuamèz tèt ak kou28 etid
- Ensifizyans kadyak26 etid
- Obèsite25 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.